• Cube Labs launched Serescentia, a wholly owned unit, to commercialize health, wellness, healthy-aging products across Europe.
• New vehicle capitalized at EUR 10,000; adds distribution and international commercialization to Cube Labs’ venture-building model.
• Scouting acquisition targets in longevity, nutraceuticals; three early targets identified with revenue of EUR 0.5 million to EUR 3.5 million.
• Growth funding planned via a mix of proceeds from Cube Labs’ ongoing capital increase, bank debt.
• Platform to integrate Cube Labs’ proprietary AI via Hiperforming Research to support marketing, sales, customer insight, post-sale service.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cube Labs S.p.A. published the original content used to generate this news brief via SDIR, the Italian regulatory disclosure system (Ref. ID: 20282-28-2026_TELEBORSA.pdf), on July 24, 2026, and is solely responsible for the information contained therein.